ABSTRACT
Recent findings have shown an inverse association between circulating C15:0/C17:0 fatty acids with disease risk, therefore, their origin needs to be determined to understanding their role in these pathologies. Through combinations of both animal and human intervention studies, we comprehensively investigated all possible contributions of these fatty acids from the gut-microbiota, the diet, and novel endogenous biosynthesis. Investigations included an intestinal germ-free study and a C15:0/C17:0 diet dose response study. Endogenous production was assessed through: a stearic acid infusion, phytol supplementation, and a Hacl1-/- mouse model. Two human dietary intervention studies were used to translate the results. Finally, a study comparing baseline C15:0/C17:0 with the prognosis of glucose intolerance. We found that circulating C15:0/C17:0 levels were not influenced by the gut-microbiota. The dose response study showed C15:0 had a linear response, however C17:0 was not directly correlated. The phytol supplementation only decreased C17:0. Stearic acid infusion only increased C17:0. Hacl1-/- only decreased C17:0. The glucose intolerance study showed only C17:0 correlated with prognosis. To summarise, circulating C15:0 and C17:0 are independently derived; C15:0 correlates directly with dietary intake, while C17:0 is substantially biosynthesized, therefore, they are not homologous in the aetiology of metabolic disease. Our findings emphasize the importance of the biosynthesis of C17:0 and recognizing its link with metabolic disease.
Subject(s)
Dietary Sugars/metabolism , Fatty Acids/metabolism , Gastrointestinal Microbiome , Glucose Intolerance , Animals , Biosynthetic Pathways , Diet , Dietary Fats/administration & dosage , Dietary Fats/metabolism , Dietary Sugars/administration & dosage , Dietary Supplements , Glucose Tolerance Test , Humans , Mice , RatsABSTRACT
Vehicles can deliver the drug molecules into cells, yet immunoreaction of the commonly used capping agents and release triggers limit their biomedical use. This shortcoming might be circumvented through replacing these chemicals with certain biomolecules. Here, we show a new and facile way to encapsulate the drug delivery vehicles and release the cargos in a highly controllable manner via modulating supramolecular interactions between enzyme, substrate, and vehicle. The cargo release from the vehicles within cells can be achieved upon substrate treatment. Yeast cells were used, allowing for a fast and cost-effective way for imaging and morphological analysis. We believe this new platform can be readily extended to various carrier systems for different purposes based on shifting the recognition pattern of enzyme-substrate pairs.
